Table 1. Demographic and clinical characteristics according to preoperative treatment.
| Variables | nCRT + MIE (RM) (N=76) |
nCT + MIE (CM) (N=42) |
nCT + OE (CO) (N=57) |
P | |||
|---|---|---|---|---|---|---|---|
| RM vs. CM | RM vs. CO | CM vs. CO | |||||
| Median year of treatment | 2015 | 2013 | 2013 | − | − | − | |
| Median follow-up [range, months] | 19 [1–79] | 43 [3–73] | 44 [1–81] | 0.001 | 0.001 | 0.623 | |
| Gender, n (%) | 0.443 | 0.380 | 0.135 | ||||
| Male | 64 (84.2) | 33 (78.6) | 51 (89.5) | ||||
| Female | 12 (15.8) | 9 (21.4) | 6 (10.5) | ||||
| Age (years) | 0.932 | 0.582 | 0.579 | ||||
| ≤60, n (%) | 35 (46.1) | 19 (45.2) | 29 (50.9) | ||||
| >60, n (%) | 41 (53.9) | 23 (54.8) | 28 (49.1) | ||||
| Median [range] | 61 [44–79] | 61 [46–73] | 60 [41–73] | ||||
| Smoking history, n (%) | 0.237 | 0.912 | 0.223 | ||||
| Yes | 22 (28.9) | 8 (19.0) | 17 (29.8) | ||||
| No | 54 (71.1) | 34 (81.0) | 40 (70.2) | ||||
| Drinking history, n (%) | 0.356 | 0.898 | 0.323 | ||||
| Yes | 14 (18.4) | 5 (11.9) | 11 (19.3) | ||||
| No | 62 (81.6) | 37 (88.1) | 46 (80.7) | ||||
| ASA grade, n (%) | 0.989 | 0.881 | 0.932 | ||||
| I | 24 (31.6) | 13 (30.9) | 19 (33.3) | ||||
| II | 48 (63.2) | 27 (64.3) | 36 (63.2) | ||||
| III | 4 (5.2) | 2 (4.8) | 2 (3.5) | ||||
| Tumor location, n (%) | 0.923 | 0.334 | 0.637 | ||||
| Upper | 13 (17.1) | 6 (14.3) | 5 (8.8) | ||||
| Middle | 44 (57.9) | 25 (59.5) | 34 (59.6) | ||||
| Lower | 19 (25.0) | 11 (26.2) | 18 (31.6) | ||||
| Clinical T stage, n (%) | 0.602 | 0.716 | 0.856 | ||||
| cT3 | 47 (61.8) | 28 (66.7) | 37 (64.9) | ||||
| cT4a | 29 (38.2) | 14 (33.3) | 20 (35.1) | ||||
| Clinical N stage, n (%) | 0.497 | 0.545 | 0.246 | ||||
| N0 | 32 (42.1) | 15 (35.7) | 27 (47.4) | ||||
| N+ | 44 (57.9) | 27 (64.3) | 30 (52.6) | ||||
nCT, neoadjuvant chemotherapy; nCRT, neoadjuvant chemoradiotherapy; MIE, minimally invasive esophagectomy; OE, open esophagectomy.